Once-daily pill could transform treatment for people with complex HIV regimens

• A new study suggests that a once-daily single-tablet HIV treatment could effectively replace more complex, multi-tablet regimens.
• Nearly 96% of participants who switched to the simplified single-pill regimen maintained viral control, with no new drug resistance detected and improved lipid profiles.
• Participants reported that taking a single pill once a day was easier and more convenient, which may help support consistent adherence to treatment.

Many people living with HIV are now able to manage the virus using antiretroviral therapy (ART). Typically, this involves taking a combination of medications on a regular schedule.

Although single-tablet regimens have been available for HIV over the past two decades, they are not suitable for everyone. A subset of individuals, particularly those diagnosed early in the HIV epidemic, still rely on complex regimens, which may involve multiple pills or injections.

These individuals may not be suitable for single-tablet regimens due to drug resistance or other medical issues. However, these multi-drug regimens can increase the risk of side effects and interactions, particularly in older adults managing additional health conditions, such as high blood pressure, diabetes, or kidney disease.

However, the results of a phase 3 clinical trial, presented at the Conference on Retroviruses and Opportunistic Infections 2026 in Denver, Colorado, and published in The Lancet, may offer an alternative.

The researchers suggest that a new single-pill combination treatment could be as effective as multi-tablet therapy, with similar safety outcomes in this cohort, which may support consistent adherence to this regimen.